Drug Trial Radar · NCT03822975
Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI
Last checked: Nov 20, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,016
Actual
Start
Feb 14, 2019
Primary completion
May 7, 2022
Study completion May 6, 2023
Sponsor
- Lead sponsor
- Shenyang Northern HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 30, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is aimed to investigate if the bivaliruding with prolonged full dose infusion after PCI is superior to heparin alone in reducing 30-day mortality or major bleeding for patients with STEMI treated with emergency PCI. A total of 6000 STEMI patients will be enrolled and randomly assigned to receive bivalirudin or heparin during emergency PCI in a 1:1 ratio. This study will provide key evidence for peri-operative anticoagulant therapy decisions in STEMI patients.
Conditions
- ST Elevation Myocardial Infarction
Interventions
BivalirudinDrug
Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.35 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is \>225 seconds.
unfractionated HeparinDrug
Heparin 70 U/kg is started before coronary angiography. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of 1000 U of heparin is administered, and the ACT re-checked to ensure it is \>225 seconds.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of all-cause death or BARC type 3~5 bleedingTime frame: 30 days
Locations
85 sites in 1 country. Site status is shown where the registry gives one.
Bengbu Second People's Hospital
Bengbu, Anhui, China
Fu Yang People'S Hospital
Fuyang, Anhui, China
Linquan County Peoples Hospital
Fuyang, Anhui, China
NO.2 People's Hospital of Fuyang City
Fuyang, Anhui, China
Taihe County People'S Hospital
Fuyang, Anhui, China
Bozhou Peoples Hospital
Haozhou, Anhui, China
Huainan Oriental Hospital Group Affiliated Hospital of Anhui University of Science & Technology
Huainan, Anhui, China
The First Hospital of Anhui University of Science&Technology
Huainan, Anhui, China
Suzhou Municipal Hospital
Suzhou, Anhui, China
Beijing Luhe Hospital.Capital Medical University
Beijing, Beijing Municipality, China
Peking University Third Hospital Yanqing Hospital
Beijing, Beijing Municipality, China
Chongqing University Fuling Hospital
Chongqing, Chongqing Municipality, China
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
Meizhou Peopie's Hospital
Meizhou, Guangdong, China
Yulin First People's Hospital
Yulin, Guangxi, China
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
Affiliated Hospital Ofzunyi Medical University
Zunyi, Guizhou, China
Hengshuicardiovascularhospital
Hengshui, Hebei, China
Jiaozuo People's Hospital
Jiaozuo, Henan, China
Kaifeng Central Hospital
Kaifeng, Henan, China
Luohe Central Hospital
Luohe, Henan, China
The First People'S Hospital of Ruzhou
Ruzhou, Henan, China
Shangqiu first people's Hospital
Shangqiu, Henan, China
The Third Affiliated Hospital Of Xinxiang Medical University
Xinxiang, Henan, China
Yuzhoucitypeopleshospital
Yuzhou, Henan, China
Fuwai Central China Cardiovascular Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University Center 1
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University Center 2
Zhengzhou, Henan, China
The First People'S Hospital of Xinmi
Zhengzhou, Henan, China
Itchoshtal Tonjinee Colere Hoatono Innehatyor Seene Ano Thohholdcy
Wuhan, Hubei, China
Tongji Hospital Tongji Medical College of Hust
Wuhan, Hubei, China
Wuhanasia Heart Hospital
Wuhan, Hubei, China
Lou Di Central Hospital
Loudi, Hunan, China
Xiangtan Central Hospital
Xiangtan, Hunan, China
Yueyang Central Hospital
Yueyang, Hunan, China
Chifeng College Affiliated Hospital
Chifeng, Inner Mongolia, China
Nanjing Firsthospital
Nanjing, Jiangsu, China
Jiangsutaizhou Peoples Hospital
Taizhou, Jiangsu, China
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
First Affiliated Hospital Of Gannan Medical University
Ganzhou, Jiangxi, China
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.